These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 15852050)
1. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Lacey LA; Wolf A; O'shea D; Erny S; Ruof J Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050 [TBL] [Abstract][Full Text] [Related]
2. Orlistat for the treatment of obesity: cost utility model. Foxcroft DR Obes Rev; 2005 Nov; 6(4):323-8. PubMed ID: 16246217 [TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach. Hertzman P Pharmacoeconomics; 2005; 23(10):1007-20. PubMed ID: 16235974 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. van Baal PH; van den Berg M; Hoogenveen RT; Vijgen SM; Engelfriet PM Value Health; 2008 Dec; 11(7):1033-40. PubMed ID: 18494748 [TBL] [Abstract][Full Text] [Related]
5. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Brennan A; Ara R; Sterz R; Matiba B; Bergemann R Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345 [TBL] [Abstract][Full Text] [Related]
6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013 [TBL] [Abstract][Full Text] [Related]
7. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328 [TBL] [Abstract][Full Text] [Related]
8. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710 [TBL] [Abstract][Full Text] [Related]
9. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
10. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259 [TBL] [Abstract][Full Text] [Related]
11. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983 [TBL] [Abstract][Full Text] [Related]
12. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Johansson K; Sundström J; Neovius K; Rössner S; Neovius M Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Maetzel A; Ruof J; Covington M; Wolf A Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990 [TBL] [Abstract][Full Text] [Related]
14. Effect of orlistat on cardiovascular disease risk in obese adults. Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142 [TBL] [Abstract][Full Text] [Related]